ArticleVaccine2021
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07485855 (Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.Blood cancer journal · 2022Pooled it
- Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study.JMIR research protocols · 2026Article
- Chronic lymphocytic leukemia and associated chronic lung diseases.Haematologica · 2025Article
- Chronic Diseases and Influenza Vaccines.Vaccines · 2025Review
- Monoclonal B-Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect.Hematological oncology · 2025Review
- Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia.Blood neoplasia · 2025Article
- Early Immune Cell and Antibody Kinetics Following SARS-CoV-2 Vaccination in Healthy Adults and Low-Count Monoclonal B-Cell Lymphocytosis.International journal of molecular sciences · 2025Article
- Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- How does geographical diversity shape vaccine efficacy?Clinical and experimental vaccine research · 2024Review
- Vaccinations in patients with chronic lymphocytic leukemia.Seminars in hematology · 2024Review
- Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.PLoS medicine · 2023Observational
- COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.Biology · 2023Review
- Understanding the Impact of COVID-19 on Chronic Lymphocytic Leukemia (CLL) Caregiving and Related Resource Needs.Journal of clinical medicine · 2023Article
- Immunogenicity profile after COVID-19 vaccination in patients with onco-hematological diseases.Einstein (Sao Paulo, Brazil) · 2023Article
- Article
- SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.medRxiv : the preprint server for health sciences · 2022Article
- Article
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia · 2022Review
- Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.Haematologica · 2022Article
- Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.Current oncology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLimited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).
methodsA prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays.
resultsThirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL.
conclusionsImmunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.